论文部分内容阅读
目的考察流行性感冒(流感)病毒裂解疫苗安尔来福TM在人群中应用的安全性。方法在14个设区的市,选择婴幼儿、儿童、少年、成人、老年人,按照程序接种流感病毒裂解疫苗,然后进行7d安全性观察,评价不良反应发生情况。结果观察对象2794人,年龄范围为6月龄～90岁。接种疫苗后总不良反应发生率为6.6%,以轻度反应最多,未见严重不良反应及新的、罕见的不良反应。局部反应发生率为2.1%,其中接种部位疼痛发生率为1.7%。全身反应发生率为5.0%,其中发热率为3.8%。结论流感病毒裂解疫苗安尔来福TM安全性良好。
Objective To investigate the safety of applying Enoxaparin (TM) influenza virus influenza vaccine in the population. Methods In 14 cities with districts, infants, children, adolescents, adults and seniors were selected and influenza virus vaccine was inoculated according to the procedure. Then safety observation was carried out for 7 days to evaluate the occurrence of adverse reactions. The results of 2794 people were observed, the age range of 6 months to 90 years. The total incidence of adverse reactions after vaccination was 6.6%, with the most mild reactions, no serious adverse reactions and new and rare adverse reactions. The incidence of local reactions was 2.1%, of which the incidence of inoculation site pain was 1.7%. The incidence of systemic reactions was 5.0%, of which the fever rate was 3.8%. Conclusion The safety of influenza A virus cleavage vaccine, Anerphafloxacin, is good.